The Danish Atopy Database (DAD): Rationale and methods

Open Allergy Journal

Volumn 5, Issue 1, 2012, Pages 62-64

  Thomsen, Simon Francis ^a   Jungersted, Jakob Mutanu ^a   Clausen, Maja Lisa ^a   Agner, Tove ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Atopic dermatitis; Database; Methodology; Outpatient; Treatment

Indexed keywords

ARTICLE; ATOPIC DERMATITIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; DANISH ATOPY DATABASE; DATA BASE; DISEASE SEVERITY; FOLLOW UP; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; METHODOLOGY; OUTPATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM;

EID: 84871020972     PISSN: None     EISSN: 18748384     Source Type: Journal    
DOI: 10.2174/1874838401205010062     Document Type: Article

References (16)

1. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med 2005; 352: 2314-24.
2. Halkjær LB, Loland L, Buchvald F, et al. Development of atopic dermatitis during the first 3 years of life. Arch Dermatol 2006; 142: 561-66.
3. Rystedt I. Hand eczema and long-term prognosis in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1985; 117: 1-59.
4. Thomsen SF, Ulrik CS, Kyvik KO, et al. Importance of genetic factors in the etiology of atopic dermatitis: a twin study. Allergy Asthma Proc 2007; 28: 535-9.
5. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-6.
6. Darsow U, Wollenberg A, Simon D, et al. European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010; 24: 317-28.
7. El-Batawy MM, Bosseila MA, Mashaly HM, Hafez VS. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci 2009; 54: 76-87.
8. Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 2011; 128: 353-9.
9. Asher MI, Montefort S, Björkstén B, et al. ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry crosssectional surveys. Lancet 2006; 368: 733-43.
10. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines. " J Am Acad Dermatol 2004; 50: 391-404.
11. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD Index. Dermatolgy 1993; 186: 23-31.
12. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-6.
13. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132: 942-9.
14. de Benedictis FM, Franceschini F, Hill D, et al. EPAAC Study Group. The allergic sensitization in infants with atopic eczema from different countries. Allergy 2009; 64: 295-303.
15. Kjaer HF, Eller E, Høst A, Andersen KE, Bindslev-Jensen C. The prevalence of allergic diseases in an unselected group of 6-year-old children. The DARC birth cohort study. Pediatr Allergy Immunol 2008; 19: 737-45.
16. Pedersen CB. The Danish Cevil Registration System. Scan J Public Health 2011; 39: 22-5.